NCT03007888View on ClinicalTrials.gov

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 14, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
Advanced Parkinson's Disease
Interventions
DRUG

Sinemet

Immediate Release Tablet containing carbidopa-levodopa flexible dosing

DRUG

IPX203

Extended Release capsules containing carbidopa-levodopa flexible dosing

Trial Locations (11)

27705

Site 103, Durham

33486

Investigator 106, Boca Raton

33613

Site 108, Tampa

33980

Investigator 113, Port Charlotte

34102

Investigator 112, Naples

44106

Investigator 109, Cleveland

48334

Investigator 101, Farmington Hills

72205

Investigator 110, Little Rock

Site 114, Little Rock

98034

Site 115, Kirkland

99202

Investigator 104, Spokane

Sponsors
All Listed Sponsors
lead

Impax Laboratories, LLC

INDUSTRY

NCT03007888 - A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease | Biotech Hunter | Biotech Hunter